69 related articles for article (PubMed ID: 26897354)
1. Mathematical model of hormone sensitive prostate cancer treatment using leuprolide: A small step towards personalization.
Foryś U; Nahshony A; Elishmereni M
PLoS One; 2022; 17(2):e0263648. PubMed ID: 35167616
[TBL] [Abstract][Full Text] [Related]
2. Mathematical Prostate Cancer Evolution: Effect of Immunotherapy Based on Controlled Vaccination Strategy.
Ba Dziul D; Jakubczyk P; Chotorlishvili L; Toklikishvilie Z; Traciak J; Jakubowicz-Gil J; Chmiel-Szajner S
Comput Math Methods Med; 2020; 2020():7970265. PubMed ID: 32411286
[TBL] [Abstract][Full Text] [Related]
3. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
4. Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy.
Foryś U; Bodnar M; Kogan Y
J Math Biol; 2016 Oct; 73(4):867-83. PubMed ID: 26897354
[TBL] [Abstract][Full Text] [Related]
5. Combination of singularly perturbed vector field method and method of directly defining the inverse mapping applied to complex ODE system prostate cancer model.
Nave O; Elbaz M
J Biol Dyn; 2018 Dec; 12(1):983-1008. PubMed ID: 30384811
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of the Selkov oscillator.
Brechmann P; Rendall AD
Math Biosci; 2018 Dec; 306():152-159. PubMed ID: 30267735
[TBL] [Abstract][Full Text] [Related]
7. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
8. A cell kinetics model for prostate cancer and its application to clinical data and individual patients.
Dimonte G
J Theor Biol; 2010 May; 264(2):420-42. PubMed ID: 20176031
[TBL] [Abstract][Full Text] [Related]
9. Ability of intermittent androgen suppression to selectively create a non-trivial periodic orbit for a type of prostate cancer patients.
Hirata Y; Aihara K
J Theor Biol; 2015 Nov; 384():147-52. PubMed ID: 26319993
[TBL] [Abstract][Full Text] [Related]
10. Modeling cancer-immune responses to therapy.
dePillis LG; Eladdadi A; Radunskaya AE
J Pharmacokinet Pharmacodyn; 2014 Oct; 41(5):461-78. PubMed ID: 25281420
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccines for cancer: an overview of clinical trials.
Melero I; Gaudernack G; Gerritsen W; Huber C; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C; Faulkner I; Mellstedt H
Nat Rev Clin Oncol; 2014 Sep; 11(9):509-24. PubMed ID: 25001465
[TBL] [Abstract][Full Text] [Related]
12. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.
Kogan Y; Halevi-Tobias K; Elishmereni M; Vuk-Pavlović S; Agur Z
Cancer Res; 2012 May; 72(9):2218-27. PubMed ID: 22422938
[TBL] [Abstract][Full Text] [Related]
13. Mathematical modeling in immunotherapy of cancer: personalizing clinical trials.
Agur Z; Vuk-Pavlović S
Mol Ther; 2012 Jan; 20(1):1-2. PubMed ID: 22215048
[No Abstract] [Full Text] [Related]
14. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
Gulley JL; Drake CG
Clin Cancer Res; 2011 Jun; 17(12):3884-91. PubMed ID: 21680544
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
